Hypertensive Emergency Management

Introduction to Hydralazine

• Hydralazine is recommended for use in adults and children for the management of hypertensive emergencies, with a maximum daily dose of 300 mg in divided doses for adults and 7.5 mg/kg/day up to 200 mg/day for children, as recommended by the American Academy of Pediatrics and American Heart Association 1, 2
• The American Heart Association recommends an initial dose of 10 mg administered through slow IV infusion, with a maximum initial dose of 20 mg, for the management of hypertensive emergencies 3

Dosage and Administration

• The initial dose of hydralazine can be 25 mg three times daily, with titration upward as needed, and a maximum dose of 150 mg daily to avoid drug-induced systemic lupus erythematosus, according to the American Heart Association 2
• For children, the maximum dose is 7.5 mg/kg/day up to 200 mg/day, usually administered in four divided doses daily, as recommended by the American Academy of Pediatrics 1
• Initial IV dosing is 10-20 mg via slow IV infusion, with effects beginning within minutes, peaking at 10-80 minutes, and lasting 2-4 hours, as recommended by the American Heart Association 4
• The American Heart Association suggests repeating the dose every 4-6 hours as needed for the management of hypertensive emergencies 3

Combination Therapy and Special Considerations

• When used in combination with other medications, such as beta-blockers, the dosage of hydralazine may need to be adjusted, with three times daily administration potentially being sufficient, according to the American Heart Association 2
• For resistant hypertension, hydralazine should be used with appropriate background diuretic and beta-blocker therapy to counteract increased sympathetic tone and sodium retention, as recommended by the American Heart Association 2
• When used for heart failure with isosorbide dinitrate, the fixed-dose combination target is 75 mg hydralazine/40 mg isosorbide dinitrate three times daily, with a maximum daily dose in this combination of 225 mg hydralazine, as per the American College of Cardiology guidelines 5, 6
• Acetylator status affects dosing requirements, with slow acetylators achieving therapeutic effect at lower doses and fast acetylators potentially requiring higher doses, although specific dosing adjustments are not provided 5, 6

Safety and Monitoring

• Doses of hydralazine above 150 mg daily increase the risk of drug-induced systemic lupus erythematosus, according to the American Heart Association 2
• Regular monitoring is required with prolonged therapy, including complete blood counts and antinuclear antibody titers, as recommended by the American Heart Association 2

Efficacy and Outcomes

• Hydralazine combined with nitrates has shown a 43% relative risk reduction in all-cause mortality in heart failure patients, with a number needed to treat (NNT) of 25 to prevent one death over 10 months, based on evidence from the American College of Cardiology 5, 6
• The following table summarizes the efficacy of hydralazine in combination with nitrates: